We conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells. We identify members of known resistance pathways and additional putative resistance drivers. Among the latter were members of the P2Y purinergic receptor family of G-protein-coupled receptors (P2Y1, P2Y2, and P2Y6). P2Y receptors mediated resistance in part through a protein-kinase-C (PKC)-dependent mechanism. Moreover, PKC activation alone was sufficient to confer resistance to ALK inhibitors, whereas combined ALK and PKC inhibition restored sensitivity. We observed enrichment of gene signatures associated with several resistance drivers (including P2Y receptors) in crizotinib-resistant ALK-rearranged lung tumors compared to treatment-naive controls, supporting a role for these identified mechanisms in clinical ALK inhibitor resistance.
INTRODUCTION
An understanding of the mechanisms by which tumors harbor primary drug resistance or acquire resistance to targeted therapies is critical for predicting which patients will respond to a specific therapy and for the identification of additional targetable pathways to maximize clinical benefit (Garraway and Jä nne, 2012) . The EML4-ALK fusion protein is an oncogenic driver in a subset of non-small cell lung cancer (NSCLC) (Soda et al., 2007) . A chromosomal inversion gives rise to EML4-ALK, leading to ectopic expression of constitutively active ALK tyrosine kinase. Aberrant ALK activity, in turn, upregulates effectors of cell survival and proliferation, including the MEK/ERK and PI3K pathways (Shaw et al., 2013) .
Crizotinib is an oral MET/anaplastic lymphoma kinase (ALK) inhibitor used as first-line therapy in the treatment of advanced NSCLC harboring ALK rearrangements. In addition, newer second-generation ALK inhibitors with increased potency and selectivity against ALK are entering clinical use. Like crizotinib, these agents are ATP-competitive inhibitors of the ALK tyrosine kinase, although they are structurally distinct from crizotinib. Ceritinib (also known as LDK378) is a second-generation inhibitor that has shown remarkable activity in patients with ALK-positive lung cancer, including individuals with acquired resistance to crizotinib (Shaw et al., 2013 Solomon et al., 2014) . Ceritinib recently received U.S. Food and Drug Administration approval for use in patients with advanced ALK-rearranged NSCLC previously treated with crizotinib. However, responses to ALK inhibitors are short lived, with resistance commonly occurring within a year.
Since the introduction of crizotinib in the treatment of ALKdriven NSCLC, gene amplification or secondary mutations in Significance ALK inhibitors, including crizotinib and ceritinib, have transformed the treatment of advanced ALK-rearranged NSCLC. Unfortunately, responses to these agents are not durable, motivating efforts to characterize resistance mechanisms that inform future combinatorial treatment strategies. We assayed over 12,000 genes for the capacity to drive resistance to ALK inhibition when overexpressed in ALK-dependent lung cancer cells. Along with known resistance pathways, we identify additional resistance drivers, including several P2Y purinergic receptors acting in part via protein kinase C (PKC). Collectively, our findings identify a spectrum of mechanisms sufficient to confer resistance to ALK inhibitors in NSCLC and suggest a role for P2Y receptors and PKC signaling in resistance to these agents. EML4-ALK have been identified in approximately one-third of tumors with acquired resistance to crizotinib (Choi et al., 2010; Doebele et al., 2012; Katayama et al., 2012; Sasaki et al., 2011) . Secondary mutations have been shown in vitro to drive resistance to crizotinib, but not all confer resistance to the structurally distinct second-generation ALK inhibitors (Katayama et al., 2011 (Katayama et al., , 2012 . In addition, activation of epidermal growth factor receptor (EGFR), KIT, and insulin-like growth factor 1 receptor (IGF-1R) have been separately identified in a subset of tumors with resistance to crizotinib (Katayama et al., 2012; Lovly et al., 2014; Sasaki et al., 2011) . Resistance to second-generation ALK inhibitors is less characterized because of the recent introduction of these agents to the clinic, although secondary mutations in EML4-ALK have been identified in a subset of tumors with acquired ceritinib resistance . Notably, no mechanism of resistance to crizotinib or ceritinib has been identified in up to half of all tumors reported to date (Doebele et al., 2012; Friboulet et al., 2014; Katayama et al., 2012) . This observation motivates a broad search for additional resistance mediators that may provide opportunities for novel therapeutic approaches. We performed a large-scale functional genetic study to identify genes whose overexpression is sufficient to confer resistance to ALK inhibition.
RESULTS

A Large-Scale Functional Study to Identify Candidate Drivers of Resistance to ALK Inhibition
We aimed to identify gain-of-function mediators of resistance to ALK inhibition by systematic perturbation of gene expression. The Center for Cancer Systems Biology (CCSB)-Broad Lentiviral Expression Library is a publicly available large-scale open reading frame (ORF) library consisting of 15,885 ORFs representing 12,800 human genes (Yang et al., 2011) . To identify transcripts whose overexpression is sufficient to drive resistance to ALK inhibition, we individually introduced each ORF into an ALKdependent lung adenocarcinoma cell line (H3122) with marked sensitivity to ALK inhibitors. ORF-expressing cells were assayed for sensitivity both to crizotinib and to the second-generation ALK inhibitor, TAE684 ( Figure 1A) . A mutant form (L1152R) of EML4-ALK known to confer resistance to both crizotinib and second-generation ALK inhibitors was used as a positive control ( Figure 1B) (Sasaki et al., 2011) . See Experimental Procedures for a full description of the experimental design.
Statistical analysis of correlation among screening replicates and estimation of lentiviral infection efficiency were performed as quality-control measures ( Figure S1 ). 95% of assayed ORFs met quality-control thresholds and were evaluated for effects on sensitivity to ALK inhibition (see Experimental Procedures). Most ORF-expressing cells remained sensitive to crizotinib and TAE684 ( Figure 1C ). For H3122 cells expressing each individual ORF in the library, the differential proliferation in drug was expressed as the ratio of cell viability in the presence of drug divided by cell viability in the absence of drug. Differential proliferation for each ORF in crizotinib and TAE684 was then expressed as a Z score (% viability Z score) to normalize across the entire data set acquired during the screen (see Experimental Procedures). ORFs conferring a differential proliferation in the presence of crizotinib or TAE684 R3 SDs above the mean (% viability Z score R3) were selected as candidate mediators of resistance to ALK inhibition. A total of 75 ORFs representing 67 genes met this criterion, with 43 ORFs yielding a % viability Z score R3 for both drugs ( Figure 1D ; Figure 2A ).
Validation and Characterization of Candidate Drivers of
Resistance to ALK Inhibition in H3122 Next, we performed a validation study in which the 75 candidate ORFs were subjected to 7-point growth inhibition assays in H3122 with crizotinib and TAE684. The area under the curve (AUC) was determined for each ORF. ORFs associated with an AUC R2.5 SD above the mean for either drug (determined in parallel from a cohort of control ORFs) were considered validated resistance drivers in H3122. Overall, 61 ORFs representing 54 genes met this criterion (81% of candidate resistance ORFs identified from the initial screening study; Figure 2A ).
Validated resistance genes reflect diverse protein classes (Figure 2B) . Prominent among these are transcription factors, serinethreonine and tyrosine kinases, growth factors, and signal transduction adaptor proteins. Resistance profiles of the 54 validated resistance genes against crizotinib and TAE684 in H3122 are shown in Figure 2C . Of note, we confirmed that validated genes also drive resistance to the second-generation ALK inhibitor ceritinib, with results comparable to those with TAE684 ( Figure S2) .
A subset of the ALK resistance genes overlap with resistance drivers to MAP kinase pathway inhibition identified in BRAF mutant melanoma (Johannessen et al., 2010 (Johannessen et al., , 2013 . Among these are kinases (such as AXL, MAP3K8 [also known as COT], and RAF1), adaptor proteins (including CRKL and GAB1), and transcription factors (such as ETV1, FOS, and YAP1). This finding is not surprising, given the central role of MEK/ERK signaling in both contexts. However, there are noteworthy differences between the data sets. For example, growth factors are more prevalent in the present study and include five epidermalgrowth-factor (EGF)-related peptides ( Figure S2 ). This is consistent with prior reports suggesting a role for EGF ligands and EGFR activation in resistance to ALK inhibition (Katayama et al., 2012; Sasaki et al., 2011; Tanimoto et al., 2014; Tanizaki et al., 2012; Voena et al., 2013; Yamada et al., 2012) . More generally, these results corroborate reports implicating paracrine and autocrine mechanisms of resistance to targeted therapies (Harbinski et al., 2012; Straussman et al., 2012; Wilson et al., 2012) .
We compared resistance profiles for crizotinib and TAE684 and identified three ORFs (AXL, MST1R, and hepatocyte growth factor [HGF] ) that validated strongly as drivers of resistance to TAE684 (% viability Z score >5.5) but not crizotinib (% viability Z score <1; Figure 2D ). This discordance likely reflects the pharmacologic activity of crizotinib against AXL, MST1R, and MET (the kinase activated by HGF) (Peters and Adjei, 2012) . Similar findings for HGF-mediated resistance to ALK inhibition have been reported (Tanimoto et al., 2014; Yamada et al., 2012) .
Effects of Resistance ORFs on Reactivation of MEK/ERK and/or PI3K Pathways in H3122 Next, since oncogenic ALK dysregulation activates the MEK/ ERK and PI3K pathways (which promote cell proliferation and survival), we determined whether ectopically expressed resistance ORFs might confer resistance by reactivation of ERK and/or AKT in H3122 in the presence of TAE684. Approximately half of the resistance ORFs (including a subset of growth factors, kinases, and adaptor proteins) produced sustained ERK and/or AKT activation despite ALK inhibition, underscoring the importance of these pathways in mediating ALK-driven tumorigenesis (Figure 3 ). The remaining resistance ORFs had a minimal effect on these pathways, raising the possibility of resistance modules that bypass these effectors.
Assessment of Validated ORFs in Resistance to
Targeted Therapies in Other NSCLC Cell Systems To identify resistance mechanisms more broadly operant in ALKrearranged lung cancer, we assayed the 54 validated resistance drivers in MGH006, a second ALK-rearranged NSCLC cell line (Sequist et al., 2010) . Of these, 23 conferred resistance to ALK inhibition in MGH006, as defined by a differential proliferation in drugs R2.5 SD above the mean (determined from control ORFs) with a single dose of crizotinib or TAE684 (Experimental Procedures; Figure 4 ). MGH006 is reported to have a secondary dependence on EGFR activation and demonstrates reduced sensitivity to ALK inhibition compared to H3122 ( Figure S3 ) (Katayama et al., 2012) . This observation, coupled with the finding that ectopic ORF expression was generally lower in MGH006 compared to H3122 ( Figure S3 ), suggests that the resistance effects observed in MGH006 could be an underestimate. Alternatively, our findings might indicate that certain molecular contexts enable some resistance mechanisms over others.
Several ALK resistance drivers identified in H3122 (including AXL, CRKL, and HGF) have previously been implicated in resistance to EGFR inhibitors in EGFR mutant lung cancer (Cheung et al., 2011; Engelman et al., 2007; Zhang et al., 2012) . In addition, both the MEK/ERK and PI3K pathways are upregulated by ALK or EGFR activation in lung cancer. We hypothesized (D) % viability Z scores in the presence of crizotinib or TAE684 for each experimental ORF. % viability Z scores are defined as the normalized ratio of cell viability in drug to cell viability in drug vehicle (DMSO). % viability Z scores for replicates of the L1152R EML4-ALK positive control are shown in red. Experimental ORFs associated with a % viability Z score R3 were selected as candidate mediators of resistance. See also Figure S1 . that a subset of identified mediators of resistance to ALK inhibition in H3122 might also drive resistance to EGFR inhibition in EGFR mutant lung cancer. To test this, we expressed the ALK resistance ORFs in three EGFR mutant NSCLC lines (HCC827, HCC4006, and PC-9) and performed inhibition studies with erlotinib ( Figure 4 ; Figure S3 ). Most ORFs mediating ALK resistance in H3122 also conferred resistance to erlotinib in EGFR mutant lines, with 38 of 54 (70%) validating in at least one such line (Experimental Procedures). As the activating effects of EGF ligands are presumably blunted by EGFR inhibition, no EGF ligands identified from the ALK inhibitor screen induced resistance to erlotinib. Together, these results raise the possibility of shared mechanisms of resistance to ALK and EGFR inhibition in ALK-rearranged and EGFR mutant lung cancers, respectively.
We evaluated the expression of each resistance ORF in all five cell lines assayed in the initial screening and subsequent validation studies ( Figure S3 ). The majority of assayed ORFs are expressed in all cell systems, although a subset of ORFs demonstrates differential expression across cell lines.
Neuregulin-1 as a Resistance Driver in ALK-Dependent Lung Cancer Cell Systems
The ORF that most strongly induced resistance to ALK inhibition in both H3122 and MGH006 was neuregulin-1 (NRG1), the ligand that activates HER3. Upon ligand binding, HER3 forms heterodimers with HER2 to activate downstream signaling pathways. To confirm the ORF screening and validation findings for NRG1, we treated ALK-dependent cell lines with recombinant NRG1 peptide and assayed resistance to TAE684 (Figures 5A and 5B). Recombinant NRG1 peptide drives resistance to TAE684 in ALK-dependent NSCLC cell lines (H3122, H2228, and MGH006). NRG1 had no impact on sensitivity to TAE684 in KELLY cells (an ALK-dependent neuroblastoma cell line), suggesting a contextdependent role for NRG1 in driving resistance to ALK inhibition. The effect of NRG1 in ALK-dependent NSCLC cell lines was abrogated with the combination of TAE684 and lapatinib, which inhibits the activity of HER2 (the dimerization partner of HER3; Figures 5C and 5D ). Together, these findings suggest a role for HER2/HER3 activation in resistance to ALK inhibition. Of note, NRG1 has recently been identified as a putative driver alteration in the somatic gene fusion CD74-NRG1 in a subset of invasive mucinous lung adenocarcinoma (Fernandez-Cuesta et al., 2014) .
Purinergic P2Y Receptors as Resistance Drivers to ALK Inhibition in H3122
We also examined less characterized ALK resistance ORFs and associated pathways. Among these is P2Y2 (encoded by P2RY2), a member of the P2Y subfamily of P2 purinergic receptors. P2Y receptors are membrane-bound G-protein-coupled receptors (GPCRs) activated in response to extracellular nucleotides including ATP. They are widely expressed in a variety of tissues, including lung epithelia (Schafer et al., 2003) . A role has been postulated for P2Y receptors in mediating the activating effects of ATP in the tumor microenvironment on tumor growth (Di Virgilio, 2012) . However, a role for these proteins in drug resistance has not previously been demonstrated. There are multiple P2Y family members that are further subdivided based on coupling to Gq, Gs, or Gi (Baroja-Mazo et al., 2013) . ORFs encoding ten P2Y family members are included in the CCSB-Broad Lentiviral Expression Library. Strikingly, two additional P2Y family members (P2Y1 and P2Y6) scored highly in the initial screening study (% viability Z score, 2-3) but did not meet our threshold for initial follow-up (Z score R3; Figure S4 ).
Given this observation suggesting that three P2Y family members are capable of impacting sensitivity to ALK inhibition in H3122, we examined these GPCRs in further detail. H3122 cells expressing these P2Y receptors demonstrated a modest but reproducible decrease in sensitivity to crizotinib in short-term assays ( Figure S4 ). P2Y-mediated resistance was more apparent in colony-formation assays, where we observed increased survival of cells expressing P2Y receptors in crizotinib or ceritinib compared to the Lac Z control (most notably for P2Y1 and P2Y2; Figures 6A and 6B ).
Resistance Associated with P2Y Receptors Mediated through Protein Kinase C We sought to explore the mechanism by which P2Y receptors mediate resistance to ALK inhibition. Notably, P2Y1, P2Y2, and P2Y6 each couple to Gq to activate phospholipase C (Baroja- Mazo et al., 2013) . Prior studies suggest that P2Y receptors activate phospholipase C and protein kinase C (PKC) (Falkenburger et al., 2013) . More specifically, P2Y2 has been shown to activate PKCd in intestinal cells (Amin et al., 2013) . Indeed, we found that H3122 cells overexpressing P2Y1 or P2Y2 (although not P2Y6) had increased levels of activated PKCd (Figure 6C ). To determine whether PKC activation alone is sufficient to drive resistance to ALK inhibition, we treated H3122 cells with ceritinib in the presence of the PKC agonist phorbol 12-myristate 13-acetate (PMA). The ceritinib dose required for 50% maximal inhibition of cell proliferation (GI 50 ) was increased 10-fold in the presence of PMA ( Figure 6D ). PKC activation also conferred resistance to ceritinib in MGH006 ( Figure 6D ). PMA had no impact on basal cell proliferation in the absence of ceritinib (Figure 6E ). Using activated PKCd as a marker for PKC activity, we Protein lysates were prepared from ORF-expressing H3122 cells after treatment with 100 nM TAE684 for 8 hr. Immunoblotting was performed with antibodies against ERK2, phospho-ERK1/ ERK2, AKT, and phospho-AKT. Fluorescence signal intensity for protein bands was quantitated. (A) Ratio of pAKT/AKT immunostaining was determined for each ORF and normalized to mean pAKT/AKT determined from 13 negative controls (left). Fold increase in pAKT/AKT relative to controls is shown, with the red horizontal line representing mean pAKT/AKT from controls. (B) As in (A), except with pERK/ERK. GEFs, guanine nucleotide exchange factors. (C) Venn diagram demonstrating overlap between ORFs reactivating AKT or ERK. Resistance ORFs associated with a pAKT/AKT or pERK/ERK ratio R2.5 SD above the mean (as determined from the negative controls) were designated as ORFs reactivating AKT or ERK in the presence of TAE684, respectively. Of 54 resistance ORFs, 28 (52%) met this criteria for AKT or ERK; 14 of these 28 ORFs were associated with reactivation of both AKT and ERK and are indicated in the shaded box.
also observed increased PKC activation in populations of H3122 cells cultured to resistance with ceritinib (in addition to increased EGFR activation as previously reported; Figure 6F ; Figure S4 ; Experimental Procedures) (Katayama et al., 2012; Sasaki et al., 2011) .
Sotrastaurin (AEB071) is a pan-PKC inhibitor in clinical trials (Buder et al., 2013; Chen et al., 2014) . The resistance induced by PMA in H3122 and MGH006 was reversed by sotrastaurin, consistent with a PKC-dependent phenotype ( Figures 6D and  6G) . Furthermore, H3122 cells ectopically expressing P2Y receptors were sensitive to the combination of crizotinib and sotrastaurin ( Figure 6H ). The effect appeared specific for P2Y receptors, as this combination did not impact resistance conferred by RAF1 (another resistance driver identified from the study; Figure 6H ).
As PKCd is not included in the CCSB-Broad Lentiviral Expression Library, we tested whether overexpression of PKCd (encoded by PRKCD) is sufficient to confer resistance to ALK inhibition in H3122. We observed that overexpression of PKCd alone is not sufficient to induce resistance to TAE684 in our assay, suggesting that other PKC isoforms activated by PMA and inhibited by sotrastaurin may be driving the observed resistance ( Figure S4 ). Of note, the initial screening study also identified another PKC isoform, PKCε (encoded by PRKCE), as sufficient to drive resistance to ALK inhibition in H3122 ( Figure 2C ).
Enrichment of Gene Signatures Associated with
Resistance Drivers in ALK Inhibitor-Resistant Tumors Compared to Treatment-Naive Controls Next, we asked whether identified resistance drivers and associated pathways might play a role in clinical resistance to ALK inhibition. We used RNA sequencing (RNA-seq) to generate gene expression profiles from a cohort of ALK-rearranged lung tumors with acquired resistance to crizotinib and from treatment-naive ALK-rearranged controls (Table 1) . Specimen DFCI76 harbors a secondary EML4-ALK mutation associated with crizotinib resistance (Sasaki et al., 2011) ; all other tumors lacked secondary ALK mutations (and activating EGFR or KRAS mutations), suggesting alternative resistance mechanisms. We used single-sample gene set enrichment analysis (ssGSEA) to query gene expression signatures for enrichment in resistant tumors compared to controls (Barbie et al., 2009; Konieczkowski et al., 2014; Subramanian et al., 2005) . A total of 286 oncogenic gene signatures were evaluated, including 189 from the Molecular Signatures database (Liberzon et al., 2011) . These include signatures associated with activation of a subset of resistance drivers/pathways identified from our screen, along with a P2Y signature we derived from overexpression of P2Y receptors in H3122 (Experimental Procedures; Figure 7A ).
Among the gene signatures enriched in resistant tumors compared to controls (with a false discovery rate [FDR] %0.2) were five signatures associated with resistance drivers/pathways identified from our functional study. Two of these were independent EGFR signatures (Creighton et al., 2006; Gatza et al., 2010 Gatza et al., , 2014 , consistent with prior reports of an association between EGFR activation and clinical resistance to ALK inhibition ( Figure 7B ). We also observed the enrichment of HER2 and RAF1 signatures in resistant tumors, consistent with our findings of NRG1 (which activates HER2/HER3) and RAF1 as strong drivers of resistance to ALK inhibition (Figures 4 and 5 ) (Creighton et al., 2006; Gatza et al., 2010 Gatza et al., , 2014 . Finally, the P2Y signature we identified in H3122 cells overexpressing P2Y receptors was also enriched in crizotinib-resistant tumors (Figures 7B and 7C;  Figure S5 ; Tables S1 and S2). These findings suggest activation of transcriptional states associated with EGFR, HER2, P2Y, and RAF1 in crizotinib-resistant tumors and likely reflect underlying biological relationships between these pathways. Examination of expanded patient cohorts will be necessary to confirm these findings. Of note, many genes and pathways identified from our functional studies as resistance drivers are not represented among gene signatures used for ssGSEA, limiting a computational assessment of those genes/ pathways in resistant tumors compared to controls.
Given these results, we asked if transcripts encoding EGFR, HER2, RAF1, or P2Y receptors were increased in resistant tumors. Among these, expression of both P2RY6 and P2RY2 was significantly increased in crizotinib-resistant tumors compared to treatment-naive controls (ps = 0.021 and 0.033, respectively; Figures 7D and 7E ). This observation provides further support for activation of a P2Y gene signature in resistant tumors.
Expression signatures associated with PKC activation were not represented in the reference collection of gene signatures used for the ssGSEAs described earlier. Therefore, we queried tumor expression profiles against the compendium of expression signatures associated with chemical perturbations in the Connectivity Map (CMap) that included PKC agonists (Experimental Procedures; Table S3 ). Among the ALK-rearranged tumors were a relapsed post-ceritinib (DFCI133) specimen and a pre-ceritinib (DFCI107) specimen obtained from a single patient who previously experienced disease progression on crizotinib (Table 1) . Among >3,200 compounds profiled in CMap, the top three chemical signatures most similar to DFCI133 (compared to DFCI107) were PKC agonists (Table S4) . Although limited to a single patient, this preliminary observation is suggestive of PKC activation in a tumor with acquired resistance to ceritinib, consistent with our functional data. However, we did not identify a connection between gene signatures induced by PKC agonists and the entire cohort of unmatched resistant ALK-rearranged tumors compared to treatment-naive controls.
DISCUSSION
Patients with advanced ALK-rearranged lung cancers are treated with ALK inhibitors, including crizotinib, and newer second-generation inhibitors, such as ceritinib or alectinib (Kwak et al., 2010; Shaw et al., 2014) . As responses to these agents are generally short lived, an understanding of the mechanisms leading to drug resistance is essential for the design of therapeutic strategies to improve efficacy. Here, we present findings from a systematic large-scale functional study of resistance to ALK inhibition in ALK-rearranged lung cancer. At least 10 of the 54 ORFs identified as potential drivers of resistance to ALK inhibition represent pathways and proteins previously implicated in Heat map displaying normalized AUC for validated drivers of resistance to crizotinib (CRZ) and TAE684 (TAE) in H3122 compared to negative controls (left) as in Figure 2C . Normalized % viability for ORF-expressing cells in the indicated doses of CRZ or TAE (for MGH006) or erlotinib (ERL; for HCC827, HCC4006, and PC-9) are shown. Relative expression of each ectopic experimental ORF in each cell line is shown in Figure S3 . Of note, we were unable to demonstrate ectopic expression of L1152R EML4-ALK in MGH006 (data not shown), and no effect of this positive control ORF was, therefore, observed on resistance to ALK inhibition in MGH006. GEFs, guanine nucleotide exchange factors. See also Figure S3 .
clinical resistance to targeted therapies in lung cancer. These include the EGFR pathway (represented by five EGF ligands identified from our study), MET activation (represented by HGF), SRC-related kinases (represented by FGR, LCK, and LYN), and the AXL receptor tyrosine kinase Engelman et al., 2007; Katayama et al., 2012; Zhang et al., 2012) . These findings underscore the capacity of a functional genomic approach using appropriate cell line model systems to identify clinically relevant resistance mechanisms.
Our results provide a landscape of genes capable of driving resistance to ALK inhibition and offer multiple insights about resistance pathways. A subset of these resistance drivers define putative signal transduction networks from cell membrane to nucleus, including growth factors, receptor tyrosine kinases, adaptor proteins, serine-threonine kinases, transcription factors, and DNA/RNA binding proteins. Our findings suggest that increased expression of individual genes representing multiple nodes of these signal transduction networks is sufficient to drive resistance to ALK inhibition in an ALK-dependent lung cancer cell system. We demonstrate that a subset of these findings is also relevant in the context of resistance to EGFR inhibitors in EGFR mutant lung cancer. In particular, a number of growth factors, kinases, and adaptor proteins identified as ALK resistance drivers that re-activate MEK/ERK and/or PI3K signaling in H3122 also drive resistance to EGFR inhibition in EGFR mutant lines. This finding highlights the fundamental role of these pathways in mediating the oncogenic effects of aberrant EGFR and ALK signaling.
In total, approximately half of the resistance drivers identified from our study reactivate MEK/ERK and/or PI3K signaling in H3122. Not all resistance drivers impact these pathways, however, suggesting alternative bypass mechanisms. Members of the P2Y family of purinergic receptors and downstream PKC activation represent previously unrecognized mediators of resistance to ALK inhibition. Overexpression of P2Y receptors did not impact MEK/ERK or PI3K signaling in our assays (Figures 3A and  3B ; Figure 6C ). However, there are reports suggesting a role for P2Y receptors in EGFR transactivation and MAP kinase pathway activation in other cell systems (Buvinic et al., 2007; Kehasse et al., 2013; Peterson et al., 2010; Ratchford et al., 2010; Sham et al., 2013; Tamaishi et al., 2011) . The observed enrichment of gene signatures associated with EGFR, HER2, RAF1, and P2Y in crizotinib-resistant tumors may hint at shared resistance-associated transcriptional targets downstream of these pathways.
P2Y receptors mediate resistance, at least in part, through PKC activation. We demonstrate that PKC activation alone is sufficient to induce resistance to ALK inhibition and is overcome with combined ALK and PKC inhibition. A recent study of resistance to the BCR-ABL inhibitor imatinib in chronic myeloid leukemia revealed that upregulation of PKCh confers resistance by activation of RAF1 and MEK/ERK signaling (Ma et al., 2014) . Further work will be required to characterize the PKC isoforms driving PKC-mediated resistance in our study. In addition, larger tumor cohorts will be necessary to determine the prevalence of P2Y and/or PKC activation in clinical resistance to ALK inhibition.
In comparing resistance profiles between crizotinib and second-generation ALK inhibitors in H3122 cells, we identify HGF (which activates MET), AXL, and MST1R (also known as , and KELLY cells were exposed to increasing concentrations of NRG1 at the indicated doses of TAE684 for 5 days. Cell viability was determined with Cell Titer-Glo. Mean and SE of three replicates are shown. (B) H2228, H3122, and KELLY cells were exposed to 200 nM TAE684 in the presence or absence of 50 ng/ml NRG1 for 6 hr. Immunoblotting of cell lysates was performed with the indicated antibodies. (C) H3122 and MGH006 cells were exposed to 50 ng/ml NRG1 with or without 1 mM lapatinib in varying concentrations of TAE684 for 5 days. Cell viability was determined as in (A). Mean and SE of three replicates are shown. (D) H3122 and MGH006 cells were exposed to combinations of 200 nM TAE684, 50 ng/ml NRG1, and 1 mM lapatinib for 6 hr. Immunoblotting was performed using the indicated antibodies. RON) as three potential mechanisms of resistance to a secondgeneration ALK inhibitor that do not impact sensitivity to crizotinib. As noted earlier, increased expression of both MET and AXL has been implicated in clinical resistance to EGFR inhibitors in EGFR mutant lung cancer (Engelman et al., 2007; Zhang et al., 2012) . As crizotinib has activity against MET, AXL, and MST1R in addition to ALK, our findings suggest that crizotinib may additionally target at least three receptor tyrosine kinases that are potential drivers of resistance to ALK inhibition in H3122. This observation may have therapeutic implications if first-line treatment of advanced ALK-rearranged NSCLC shifts from crizotinib to more selective second-generation inhibitors that lack activity against AXL, MST1R, and MET. Conversely, recent work has shown that the second-generation ALK inhibitor ceritinib has activity against IGF-1R (in addition to ALK), which is a potential mechanism of resistance to crizotinib (Lovly et al., 2014) . Thus, both crizotinib and second-generation ALK inhibitors may simultaneously target distinct potential resistance drivers in addition to ALK itself.
Our findings nominate several possible agents (including inhibitors of EGFR, HER2/HER3, or PKC) that might, in principle, be combined with ALK inhibition to overcome or delay a range of resistance mechanisms. However, an emerging theme from this and other comprehensive resistance studies is that activation of multiple pathways may contribute to the drug resistance phenotype (Huang et al., 2012; Johannessen et al., 2013) . This poses a significant therapeutic challenge, as it may not be feasible to target all possible resistance pathways. The potential for ''resistance heterogeneity'' in the clinical arena may complicate identification of an optimal treatment strategy for individuals whose tumors acquire resistance to targeted therapies. Repeat biopsy at disease progression may provide an opportunity for characterization of resistant tumors to prioritize combinations for individual patients, but multiple resistance mechanisms within the same tumor could limit therapeutic efficacy (Gerlinger et al., 2012) . Detailed molecular characterization of patientderived tumors might determine the frequency at which specific resistance mechanisms occur in patients, potentially enabling prioritization of select therapeutic combinations for clinical trial design.
In the future, therapeutic disruption of resistance-associated transcriptional states may provide an alternative to targeting of individual upstream signaling pathways, inasmuch as such pathways might converge onto shared transcriptional outputs that drive tumor growth in drug-resistant states. Theoretically, this might be achieved by incorporation of chromatin-modifying agents as part of an ALK-directed treatment strategy. Such an approach that does not rely solely on inhibition of upstream signaling proteins susceptible to bypass might lead to more durable responses to targeted therapies.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents H3122 cells were obtained from the National Cancer Institute. Generation of ceritinib-resistant H3122 cells is described in the Supplemental Experimental Procedures. H2228, HCC827, and HCC4006 were purchased from the American Type Culture Collection (ATCC). PC-9 cells were obtained from Public Health England, and KELLY neuroblastoma cells were obtained from SigmaAldrich. Cells were maintained in RPMI-1640 (Cellgro) with 10% fetal bovine serum (Gemini Bioproducts) and penicillin (100 U/ml)/streptomycin (100 mg/ml) (Cellgro). MGH006 cells have been previously reported and were maintained in DMEM (Cellgro) with 10% fetal bovine serum, penicillin, and streptomycin (Sequist et al., 2010) . All cell lines were tested to confirm the absence of mycoplasma contamination. Crizotinib, TAE684, ceritinib, erlotinib, lapatinib, and sotrastaurin were purchased from Selleck Chemicals. Blasticidin was obtained from Life Technologies. PMA was purchased from Santa Cruz Biotechnology.
Screening of the CCSB-Broad Lentiviral Expression Library
The CCSB-Broad Lentiviral Expression library has been previously described (Yang et al., 2011) . Additional information is included in the Supplemental Experimental Procedures. H3122 cells were seeded in white clear-bottom 384-well microtiter plates at 1,500 cells per well using a Multidrop Combi (Thermo-Scientific). The next day, cells were spin-infected with the expression library (or L1152R EML4-ALK as a positive control) in the presence of 4 mg/ml polybrene at 2,250 rpm for 30 min at 37 C. Cells were infected in seven replicates. Virus was removed after 24 hr and replaced with standard growth media (containing 12 mg/ml blasticidin for one replicate). After an additional 48 hr, the remaining six replicates of ORF-expressing cells were treated with 0.01% DMSO (drug vehicle), 1 mM crizotinib, or 30 nM TAE684 (two replicates each). Lentiviral infection, media change, and drug addition were all performed with robotics. Following 5 days of drug exposure, cell viability was determined using the Cell Titer-Glo luminescent assay (Promega) according to the manufacturer's instructions. Luminescence was measured with an EnVision Multilabel Reader (Perkin-Elmer). Screening of the entire CCSB-Broad Lentiviral Expression Library (which is arrayed in forty-seven 384-well plates) was performed in seven batches. Identification and validation of candidate resistance ORFs (and associated statistical analyses) are described in the Supplemental Experimental Procedures.
Antibodies and Immunoblotting
Cells were lysed in 50 mM HEPES (pH 7.5), 1% Triton X-100, 10% glycerol, 150 mM NaCl, 2 mM EDTA, and 10 mM NaF with protease inhibitors (Roche) and phosphatase inhibitors (Calbiochem). Lysates were fractionated by SDS-PAGE and transferred to nitrocellulose membranes using the iBlot system (Life Technologies). Two-color immunoblotting was performed using LI-COR reagents (Odyssey Blocking Buffer and IRDye 800CW and IRDye 680RD secondary antibodies) according to the manufacturer's instructions (LI-COR Biosciences). Fluorescence detection was performed using an Odyssey CLx Infrared Imaging System, and quantitation was performed using Image Studio software (LI-COR). Antibodies against ALK (#3791), AKT (#2920), phospho-AKT (Ser 473; #4060), EGFR (#2239), phospho-EGFR (Tyr 1068; #3777), PKCd (#9616), and phospho-PKCd (Tyr 311; #2055) were obtained from Cell Signaling. ERK2 antibody (sc-154) was purchased from Santa Cruz Biotechnology. Antibodies against phospho-ERK1/ERK2 (Thr 185/Tyr 187; #M8159) and vinculin (#V9131) were obtained from Sigma. V5 antibody (#R960-25) was obtained from Life Technologies. In-cell western blotting is described in the Supplemental Experimental Procedures.
Colony-Formation Assays H3122 cells were seeded in 12-well plates at a density of 10,000-20,000 cells per well. The following day, cells were spin-infected with lentivirus harboring the indicated ORFs in the presence of 4 mg/ml polybrene. Virus was removed after 24 hr and replaced with standard growth media. After an additional 24-48 hr, cells were treated with drug or DMSO as indicated. Cells were exposed to drug or DMSO for 14-21 days, with media change and fresh drug addition every 3 days. Cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet. Cells were photographed using a Leica microscope and imaging software. Quantification of crystal violet uptake for each sample was determined by de-staining cells with 10% acetic acid and measurement of absorbance at 595 nm using a SpectraMax 190 instrument (Molecular Devices).
RNA-seq
Patients with ALK-rearranged NSCLC were identified from the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute (DFCI). Tumor samples were obtained under a protocol approved by the DFCI Institutional Review Board (IRB), and all participating patients provided written informed consent. Total RNA was extracted from fresh frozen tumor specimens using TRIzol (Life Technologies) according to the manufacturer's instructions. The presence of the EML4-ALK fusion transcript was confirmed by RT-PCR for each tumor. We also prepared total RNA from H3122 cells expressing P2Y receptors for RNA-seq. Parental H3122 cells or H3122 expressing ectopic Lac Z, P2Y1, or P2Y2 were exposed to 100 nM TAE684 for 12 hr. (Experimental samples were H3122 cells expressing P2Y1 or P2Y2; control samples were parental H3122 and H3122 cells expressing Lac Z.) Total RNA was extracted using the RNeasy kit (QIAGEN) with on-column DNase treatment.
cDNA libraries were generated for tumor and cell line samples using the TruSeq Sample Preparation Kit (Illumina) with polyA selection according to the manufacturer's protocol (Revision A). Libraries were pooled using indexed adapters for multiplexing. Pooled libraries were normalized to 2 nM and denatured using 0.2 N NaOH prior to sequencing. Flow cell cluster amplification and sequencing were performed according to the manufacturer's protocols using either the HiSeq 2000 or HiSeq 2500 to a depth of 45-50 million reads per sample (paired-end with 76 base-pair reads).
Data were analyzed using the Broad Picard Pipeline, which includes de-multiplexing and data aggregation. Reads were mapped to the reference human genome (hg19) using TopHat 1.4.1. Expression levels for each gene were denoted as RPKM (reads per kilobase of transcript per million mapped reads) values determined using Cufflinks 2.0.2. Genes that were not expressed in any patient-derived tumor samples (RPKM = 0) were removed from the tumor data set; genes not expressed in the cell line samples were removed from the cell line data set. Differential transcript expression was determined with the signal-to-noise test statistic, with an SD at least 20% of the class mean. A description of the methods used to analyze RNA-seq gene expression data is provided in the Supplemental Experimental Procedures. Figure S5 and Tables S1, S2, S3, and S4.
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